EPH95 The Role of Adjuvant Atezolizumab in Reducing Recurrence-Related Treatment Costs in Resected Early-Stage PD-L1 High Non-Small Cell Lung Cancer in Belgium
Abstract
Authors
L Herteleer M Arnold N Jovanoski
L Herteleer M Arnold N Jovanoski
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now